UMIN-CTR Clinical Trial

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000022321
Receipt No. R000025719
Official scientific title of the study International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1
Date of disclosure of the study information 2016/05/16
Last modified on 2018/11/26 (Ver. 6)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1
Title of the study (Brief title) International Retrospective Cohort Study of Conversion Therapy (Adjuvant surgery) for Stage IV Gastric Cancer 1 (CONVO-GC-1)
Region
Japan Asia(except Japan)

Condition
Condition StageIV gastric cancer
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The aim of the study is to clarify the present information of conversion therapy of stage IV gastric cancer in Asian counties, to investigate the feasibility of the therapy and to collect the baseline data for future analysis to clarify the role of the therapy.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes The rate of operative complications after conversion therapy
Key secondary outcomes Overall Survival(OS), Relapse free survival(RFS), Response rate, and Histological response

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria To clarify the meaning of conversion therapy, we need to collect all stage IV gastric cancer patients who underwent operation with successful chemoradiationtherapy.

1. Histologically proven primary gastric adenocarcinoma.

2. Stage IV gastric cancer patients initially regarded as non-curably resectable but with successful chemotherapy, regarded as curably resectable (R0), then underwent radical operation (including metastasectomy).

3. Stage IV gastric cancer patients initially regarded as resectable, underwent radical operation after chemotherapy (neoadjuvant case).

4. Stage IV gastric cancer patients with peritoneal dissemination or positive cytology by staging laparoscopy or laparotomy but with successful chemotherapy, then underwent radical operation, or patients who underwent gastrectomy irrespective of chemotherapy.
Key exclusion criteria None
Target sample size 900

Research contact person
Name of lead principal investigator Kazuhiro YOSHIDA
Organization Gifu University School of Medicine
Division name Department of Surgical Oncology
Address Yanagido 1-1, Gifu-city, Gifu
TEL 058-230-6235
Email kyoshida@gifu-u.ac.jp

Public contact
Name of contact person Mami SAKURAI
Organization Federation of Asian Clinical Oncology (FACO)
Division name Tokyo Office
Address Shinkawa Bldg. 2F, 2-13-10, Shinkawa, Chu-ku, Tokyo 104-0033 Japan
TEL 03-5542-0546
Homepage URL
Email faco-office@jsco.or.jp

Sponsor
Institute FACO(Federation of Asian Clinical Oncology)
Institute
Department

Funding Source
Organization FACO(Federation of Asian Clinical Oncology)
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 05 Month 16 Day

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2016 Year 03 Month 21 Day
Anticipated trial start date
2016 Year 04 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information Questionnaire survey (Retrospective cohort study) for patients completed adjuvant surgery from 01Jan2001 to 31Dec2014.

Surveillance items of clinical data
I. Sequence of diagnosis and treatment
II. Patients' background information at diagnosis, Tumor status: Pathological diagnosis, Lauren classification, Depth of tumor, Lymph node metastasis, Liver metastasis, Peritoneal dissemination, Tumor diameter, Location of metastasis, Diagnostic staging laparoscopy, Diagnostic method for peritoneal dissemination, Other cancers, Complication and comorbidity, Having target lesion or not, HER2 status.
III. Treatment status of chemotherapy and radiation therapy: Regimen, number of cycle, the reason of discontinuation, Dose and period of radiation therapy.
IV. Evaluation of Response: Overall response evaluated by RECIST version 1.1.
V. Surgical and Pathological Information: Type of tumor, Histological type, tumor diameter, Lymph node metastasis, number of metastasis and dissected lymph node, distant metastasis, Liver metastasis, Peritoneal dissemination, Peritoneal lavage cytology, Proximal and distal margin, Residual tumor, Reason for conversion therapy, Date of surgery, Operation time, Estimated blood loss, Volume of blood transfusion, mode of operation, Extension of lymph node dissection, Combined organ resection, Histological response.
VI. Postoperative Complications: Wound infection, Thromboembolism, Anastomotic leakage, Intraperitoneal abscess, Pancraticfistula, Postoperative pneumonia, others.
VII. Postoperative treatment status: Regimen of chemotherapy, number of cycle, Reason of discontinuation, dose and period of radiation therapy, Reason of no treatment.
VIII. Confirmation of outcome: Date last known to be alive or date of death, Cause of death, Date of tumor relapse after curative resection, recurrent site, Survival status, Method of confirmation of outcome, Tumor relapse/recurrence.

Management information
Registered date
2016 Year 05 Month 16 Day
Last modified on
2018 Year 11 Month 26 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000025719